A Study of Olaratumab (IMC-3G3) in Previously Treated Participants With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors

Stopped early · Phase 2

Conditions studied: Gastrointestinal Stromal Tumor (GIST)

In brief

The purpose of this study is to evaluate the tumor response of stable disease (SD), partial response (PR), or complete response (CR) \[according to Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST v1.1 criteria)\] at 12 weeks in participants with Gastrointestinal Stromal Tumors (GIST) harboring platelet-derived growth factor receptor alpha (PDGFRα) mutations and patients with GIST not harboring PDGFRα mutations.

Key facts

Study ID

NCT01316263

Run by

Eli Lilly and Company

People needed

21

Starts

2011-08-01

Expected to finish

2012-11-01

Last updated by the study team

2017-03-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participant has histologically or cytologically confirmed, unresectable and/or metastatic GIST
• Participant has measurable disease
• Participant has documented objective progression following, or intolerance to, treatment with both imatinib and sunitinib
• Participant's Eastern Cooperative Oncology Group (ECOG) performance status (PS) is 0 to 2
• Participant has either:
• prior results from growth factor receptor associated with tyrosine kinase activity (KIT) and PDGFRα mutation analysis that meet analytical criteria as defined for the on-study analysis of these mutations and tumor tissue (from either primary or metastatic tumor) that can be submitted for analysis within 30 days after the first dose of study therapy; or
• if prior results from KIT and PDGFRα mutation analysis are not available or do not meet analytical criteria as above, then tumor tissue (from either primary or metastatic tumor) must be submitted for genotype testing at the latest 28 days prior to the first dose of study therapy
• Participant has adequate hematologic, hepatic, renal and coagulation function
• Women of childbearing potential and sexually active males must agree to use adequate contraception prior to study and for at least 12 weeks after the last dose of IMC-3G3
• Participant has a life expectancy of ≥ 3 months

You may not qualify if…

• Participant has untreated central nervous system metastases, and as a result, is clinically unstable with regard to neurologic function
• Participant has a history of another primary cancer
• Participant has received any investigational therapy within 14 days prior to registration, or is currently enrolled in any other type of medical research
• Participant is receiving concurrent treatment with other anticancer therapy
• Participant has known human immunodeficiency virus (HIV) infection
• Participant has undergone major surgery within 28 days prior to registration
• If female, participant is pregnant or breastfeeding

Where it is running

• ImClone Investigational Site — Chicago, Illinois, United States
• ImClone Investigational Site — Boston, Massachusetts, United States
• ImClone Investigational Site — Edegem, Belgium
• ImClone Investigational Site — Leuven, Belgium
• ImClone Investigational Site — Bad Saarow, Germany
• ImClone Investigational Site — Berlin, Germany
• ImClone Investigational Site — Essen, Germany
• ImClone Investigational Site — Mannheim, Germany
• ImClone Investigational Site — Tübingen, Germany
• ImClone Investigational Site — Leiden, Netherlands
• ImClone Investigational Site — Warsaw, Poland
• ImClone Investigational Site — Madrid, Spain
• ImClone Investigational Site — Madrid, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.